Skip to main content
Erschienen in: The Indian Journal of Pediatrics 5/2017

08.02.2017 | Original Article

Inflammatory Markers and Disease Activity in Juvenile Idiopathic Arthritis

verfasst von: Sumantra Sarkar, Md. Mahboob Alam, Gargi Das, Supratim Datta

Erschienen in: Indian Journal of Pediatrics | Ausgabe 5/2017

Einloggen, um Zugang zu erhalten

Abstract

Objective

To evaluate the post treatment changes in disease activity and inflammatory markers over time in longitudinal follow-up involving different subtypes of juvenile idiopathic arthritis (JIA) patients.

Methods

This prospective longitudinal study, carried out over a period of 2 y, included JIA patients, both old and new, with high disease activity. Erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), ferritin, CHAQ (Childhood Health Assessment Questionnaire) score and JADAS27 (Juvenile Arthritis Disease Activity score with 27 active joint counts) were estimated at the initial visit, 6 mo, 12 mo and 18 mo of follow-up.

Results

Out of 40 patients, 10 had persistent oligoarthritis, 11 had rheumatoid factor (RF) positive polyarthritis, 8 had RF negative polyarthritis and 11 had systemic JIA. Twenty-one of them were females. Serum ferritin was highly elevated in systemic JIA patients with a range of 750–7712 ng/ml at the initial visit. All three inflammatory markers with disease activity score decreased significantly over 18-mo-period in all four subtypes. At any visit, all these parameters had largest value in systemic arthritis and least in oligoarthritis variety. At 18 mo, all oligoarthritis and polyarthritis cases had low or inactive disease while none of the systemic JIA patients achieved inactive disease. Elevated ESR and serum ferritin was found in all at 18 mo. CRP normalized in some with low or moderate disease activity.

Conclusions

Inflammatory markers and disease activity decreased in all subtypes of JIA with treatment without biologics. Acute phase markers often remain elevated in inactive disease state. Similarly, normal level of an inflammatory marker does not necessarily indicate absence of active disease.
Literatur
1.
Zurück zum Zitat Petty RE, Southwood TR, Manners P, et al. International league of Association for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31:390–2.PubMed Petty RE, Southwood TR, Manners P, et al. International league of Association for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31:390–2.PubMed
2.
Zurück zum Zitat Duffy CM, Colbert RA, Laxer RM, Schanberg LE, Bowyer SL. Nomenclature and classification in chronic childhood arthritis: time for a change? Arthritis Rheum. 2005;52:382–5.CrossRefPubMed Duffy CM, Colbert RA, Laxer RM, Schanberg LE, Bowyer SL. Nomenclature and classification in chronic childhood arthritis: time for a change? Arthritis Rheum. 2005;52:382–5.CrossRefPubMed
3.
Zurück zum Zitat Consolaro A, Ruperto N, Bazso A, et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum. 2009;61:658–66.CrossRefPubMed Consolaro A, Ruperto N, Bazso A, et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum. 2009;61:658–66.CrossRefPubMed
4.
Zurück zum Zitat Nordal EB, Zak M, Aalto K, et al. Validity and predictive ability of the juvenile arthritis disease activity score based on CRP versus ESR in a Nordic population-based setting. Ann Rheum Dis. 2012;71:1122–7.CrossRefPubMed Nordal EB, Zak M, Aalto K, et al. Validity and predictive ability of the juvenile arthritis disease activity score based on CRP versus ESR in a Nordic population-based setting. Ann Rheum Dis. 2012;71:1122–7.CrossRefPubMed
5.
Zurück zum Zitat Viola S, Felici E, Magni-Manzoni S, et al. Development and validation of a clinical index for assessment of long-term damage in juvenile idiopathic arthritis. Arthritis Rheum. 2005;52:2092–102.CrossRefPubMed Viola S, Felici E, Magni-Manzoni S, et al. Development and validation of a clinical index for assessment of long-term damage in juvenile idiopathic arthritis. Arthritis Rheum. 2005;52:2092–102.CrossRefPubMed
6.
Zurück zum Zitat Susic GZ, Stojanovic RM, Pejnovic NN, et al. Analysis of disease activity, functional disability and articular damage in patients with juvenile idiopathic arthritis: a prospective outcome study. Clin Exp Rheumatol. 2011;29:337–44.PubMed Susic GZ, Stojanovic RM, Pejnovic NN, et al. Analysis of disease activity, functional disability and articular damage in patients with juvenile idiopathic arthritis: a prospective outcome study. Clin Exp Rheumatol. 2011;29:337–44.PubMed
7.
Zurück zum Zitat Bazso A, Consolaro A, Ruperto N, et al. Development and testing of reduced joint counts in juvenile idiopathic arthritis. J Rheumatol. 2009;36:183–90.PubMed Bazso A, Consolaro A, Ruperto N, et al. Development and testing of reduced joint counts in juvenile idiopathic arthritis. J Rheumatol. 2009;36:183–90.PubMed
8.
Zurück zum Zitat Lomater C, Gerloni V, Gattinara M, Mazzotti J, Cimaz R, Fantini F. Systemic onset juvenile idiopathic arthritis: a retrospective study of 80 consecutive patients followed for 10 years. J Rheumatol. 2000;27:491–6.PubMed Lomater C, Gerloni V, Gattinara M, Mazzotti J, Cimaz R, Fantini F. Systemic onset juvenile idiopathic arthritis: a retrospective study of 80 consecutive patients followed for 10 years. J Rheumatol. 2000;27:491–6.PubMed
9.
Zurück zum Zitat Flatø B, Lien G, Smerdel A, et al. Prognostic factors in juvenile rheumatoid arthritis: a case-control study revealing early predictors and outcome after 14.9 years. J Rheumatol. 2003;30:386–93.PubMed Flatø B, Lien G, Smerdel A, et al. Prognostic factors in juvenile rheumatoid arthritis: a case-control study revealing early predictors and outcome after 14.9 years. J Rheumatol. 2003;30:386–93.PubMed
10.
Zurück zum Zitat Wallace CA, Ruperto N, Giannini EH. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol. 2004;31:2290–4.PubMed Wallace CA, Ruperto N, Giannini EH. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol. 2004;31:2290–4.PubMed
11.
Zurück zum Zitat Pouchot J, Ecosse E, Coste J, Guillemin F, French Quality of Life Study Group, Paediatric Rheumatology International Trials Organisation. Validity of the childhood health assessment questionnaire is independent of age in juvenile idiopathic arthritis. Arthritis Rheum. 2004;51:519–26.CrossRefPubMed Pouchot J, Ecosse E, Coste J, Guillemin F, French Quality of Life Study Group, Paediatric Rheumatology International Trials Organisation. Validity of the childhood health assessment questionnaire is independent of age in juvenile idiopathic arthritis. Arthritis Rheum. 2004;51:519–26.CrossRefPubMed
12.
Zurück zum Zitat Consolaro A, Bracciolini G, Ruperto N, et al. Remission, minimal disease activity and acceptable symptom state in juvenile idiopathic arthritis. Arthritis Rheum. 2012;64:2366–74.CrossRefPubMed Consolaro A, Bracciolini G, Ruperto N, et al. Remission, minimal disease activity and acceptable symptom state in juvenile idiopathic arthritis. Arthritis Rheum. 2012;64:2366–74.CrossRefPubMed
13.
Zurück zum Zitat Consolaro A, Ruperto N, Bracciolini G, et al. Paediatric rheumatology international trials organization (PRINTO). Defining criteria for high disease activity in juvenile idiopathic arthritis based on the juvenile arthritis disease activity score. Ann Rheum Dis. 2014;73:1380–3.CrossRefPubMed Consolaro A, Ruperto N, Bracciolini G, et al. Paediatric rheumatology international trials organization (PRINTO). Defining criteria for high disease activity in juvenile idiopathic arthritis based on the juvenile arthritis disease activity score. Ann Rheum Dis. 2014;73:1380–3.CrossRefPubMed
14.
Zurück zum Zitat Pelkonen P, Swanljung K, Siimes MA. Ferritinemia as an indicator of systemic disease activity in children with systemic juvenile rheumatoid arthritis. Acta Paediatr Scand. 1986;75:64–8.CrossRefPubMed Pelkonen P, Swanljung K, Siimes MA. Ferritinemia as an indicator of systemic disease activity in children with systemic juvenile rheumatoid arthritis. Acta Paediatr Scand. 1986;75:64–8.CrossRefPubMed
15.
Zurück zum Zitat Zhou YF, Li CF, Wang J, et al. Value of serum ferritin in measuring the activation and prognosis in systemic onset juvenile idiopathic arthritis. Zhonghua Yi Xue Za Zhi. 2013;93:2487–9.PubMed Zhou YF, Li CF, Wang J, et al. Value of serum ferritin in measuring the activation and prognosis in systemic onset juvenile idiopathic arthritis. Zhonghua Yi Xue Za Zhi. 2013;93:2487–9.PubMed
16.
Zurück zum Zitat Wallace CA, Huang B, Bandeira M, Ravelli A, Giannini EH. Patterns of clinical remission in select categories of juvenile idiopathic arthritis. Arthritis Rheum. 2005;52:3554–62.CrossRefPubMed Wallace CA, Huang B, Bandeira M, Ravelli A, Giannini EH. Patterns of clinical remission in select categories of juvenile idiopathic arthritis. Arthritis Rheum. 2005;52:3554–62.CrossRefPubMed
17.
Zurück zum Zitat Fantini F, Gerloni V, Gattinara M, Cimaz R, Arnoldi C, Lupi E. Remission in juvenile chronic arthritis: a cohort study of 683 consecutive cases with a mean follow-up of 10 years. J Rheumatol. 2003;30:579–84.PubMed Fantini F, Gerloni V, Gattinara M, Cimaz R, Arnoldi C, Lupi E. Remission in juvenile chronic arthritis: a cohort study of 683 consecutive cases with a mean follow-up of 10 years. J Rheumatol. 2003;30:579–84.PubMed
18.
Zurück zum Zitat Packham JC, Hall MA. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: functional outcome. Rheumatology. 2002;41:1428–35.CrossRefPubMed Packham JC, Hall MA. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: functional outcome. Rheumatology. 2002;41:1428–35.CrossRefPubMed
19.
Zurück zum Zitat Foster HE, Marshall N, Myers A, Dunklet P, Griffiths ID. Outcome in adults with juvenile idiopathic arthritis: a quality of life study. Arthritis Rheum. 2003;48:767–75.CrossRefPubMed Foster HE, Marshall N, Myers A, Dunklet P, Griffiths ID. Outcome in adults with juvenile idiopathic arthritis: a quality of life study. Arthritis Rheum. 2003;48:767–75.CrossRefPubMed
20.
Zurück zum Zitat Sherry DD, Stein LD, Reed AM, Schanberg LE, Kredich DW. Prevention of leg length discrepancy in young children with pauciarticular juvenile rheumatoid arthritis by treatment with intraarticular steroids. Arthritis Rheum. 1999;42:2330–4.CrossRefPubMed Sherry DD, Stein LD, Reed AM, Schanberg LE, Kredich DW. Prevention of leg length discrepancy in young children with pauciarticular juvenile rheumatoid arthritis by treatment with intraarticular steroids. Arthritis Rheum. 1999;42:2330–4.CrossRefPubMed
21.
Zurück zum Zitat Ungar WJ, Costa V, Burnett HF, Feldman BM, Laxer RM. The use of biologic response modifiers in polyarticular-course juvenile idiopathic arthritis: a systematic review. Semin Arthritis Rheum. 2013;42:597–618.CrossRefPubMed Ungar WJ, Costa V, Burnett HF, Feldman BM, Laxer RM. The use of biologic response modifiers in polyarticular-course juvenile idiopathic arthritis: a systematic review. Semin Arthritis Rheum. 2013;42:597–618.CrossRefPubMed
22.
Zurück zum Zitat Kearsley-Fleet L, Davies R, Lunt M, Southwood TR, Hyrich KL. Factors associated with improvement in disease activity following initiation of etanercept in children and young people with juvenile idiopathic arthritis: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study. Rheumatology (Oxford). 2016;55:840–7.CrossRef Kearsley-Fleet L, Davies R, Lunt M, Southwood TR, Hyrich KL. Factors associated with improvement in disease activity following initiation of etanercept in children and young people with juvenile idiopathic arthritis: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study. Rheumatology (Oxford). 2016;55:840–7.CrossRef
23.
Zurück zum Zitat Woerner A, Uettwiller F, Melki I, et al. Biological treatment in systemic juvenile idiopathic arthritis: achievement of inactive disease or clinical remission on a first, second or third biological agent. RMD Open. 2015;1:e000036.CrossRefPubMedPubMedCentral Woerner A, Uettwiller F, Melki I, et al. Biological treatment in systemic juvenile idiopathic arthritis: achievement of inactive disease or clinical remission on a first, second or third biological agent. RMD Open. 2015;1:e000036.CrossRefPubMedPubMedCentral
Metadaten
Titel
Inflammatory Markers and Disease Activity in Juvenile Idiopathic Arthritis
verfasst von
Sumantra Sarkar
Md. Mahboob Alam
Gargi Das
Supratim Datta
Publikationsdatum
08.02.2017
Verlag
Springer India
Erschienen in
Indian Journal of Pediatrics / Ausgabe 5/2017
Print ISSN: 0019-5456
Elektronische ISSN: 0973-7693
DOI
https://doi.org/10.1007/s12098-017-2292-6

Weitere Artikel der Ausgabe 5/2017

The Indian Journal of Pediatrics 5/2017 Zur Ausgabe

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

23.04.2024 Typ-1-Diabetes Nachrichten

Wenn Kinder an Werktagen zum Arzt gehen, werden neu auftretender Typ-1-Diabetes und diabetische Ketoazidosen häufiger erkannt als bei Arztbesuchen an Wochenenden oder Feiertagen.

Neue Studienergebnisse zur Myopiekontrolle mit Atropin

22.04.2024 Fehlsichtigkeit Nachrichten

Augentropfen mit niedrig dosiertem Atropin können helfen, das Fortschreiten einer Kurzsichtigkeit bei Kindern zumindest zu verlangsamen, wie die Ergebnisse einer aktuellen Studie mit verschiedenen Dosierungen zeigen.

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

18.04.2024 Spinale Muskelatrophien Nachrichten

Seit 2021 ist die Untersuchung auf spinale Muskelatrophie Teil des Neugeborenen-Screenings in Deutschland. Eine Studie liefert weitere Evidenz für den Nutzen der Maßnahme.

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

18.04.2024 Pädiatrische Notfallmedizin Nachrichten

Im Choosing-Wisely-Programm, das für die deutsche Initiative „Klug entscheiden“ Pate gestanden hat, sind erstmals Empfehlungen zum Umgang mit Notfällen von Kindern erschienen. Fünf Dinge gilt es demnach zu vermeiden.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.